CR10560A - Inhibidores de tirosina quinasa - Google Patents

Inhibidores de tirosina quinasa

Info

Publication number
CR10560A
CR10560A CR10560A CR10560A CR10560A CR 10560 A CR10560 A CR 10560A CR 10560 A CR10560 A CR 10560A CR 10560 A CR10560 A CR 10560A CR 10560 A CR10560 A CR 10560A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
relates
thyrosine kinase
met
thyrosine
Prior art date
Application number
CR10560A
Other languages
English (en)
Inventor
Christopher J Dinsmore
Matthew H Katcher
Alan B Northrup
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR10560A publication Critical patent/CR10560A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invencion se refiere a derivados de 5H-benzo[4,5]ciclohepta[1,2-b]piridina, que son utiles para tratar enfermedades proliferativas celulares, para tratar trastornos asociados con actividad MET, y para inhibir la tirosina quinasa de receptor MET. La invencion se refiere tambien a composiciones las cuales comprenden estos compuestos, y procedimientos de usarlos para tratar cancer en mamiferos.
CR10560A 2006-07-10 2009-01-14 Inhibidores de tirosina quinasa CR10560A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81976406P 2006-07-10 2006-07-10

Publications (1)

Publication Number Publication Date
CR10560A true CR10560A (es) 2009-02-26

Family

ID=38923821

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10560A CR10560A (es) 2006-07-10 2009-01-14 Inhibidores de tirosina quinasa

Country Status (24)

Country Link
US (2) US8222269B2 (es)
EP (1) EP2049494B1 (es)
JP (2) JP4203121B1 (es)
KR (1) KR20090026187A (es)
CN (1) CN101535268B (es)
AR (1) AR061804A1 (es)
AU (1) AU2007273081B2 (es)
BR (1) BRPI0713941A2 (es)
CA (1) CA2656578C (es)
CO (1) CO6190518A2 (es)
CR (1) CR10560A (es)
EC (1) ECSP099051A (es)
ES (1) ES2497493T3 (es)
GT (1) GT200900004A (es)
HN (1) HN2009000018A (es)
IL (1) IL196337A0 (es)
MA (1) MA30631B1 (es)
MX (1) MX2009000410A (es)
NO (1) NO20090608L (es)
PE (1) PE20080275A1 (es)
RU (1) RU2009104303A (es)
TW (1) TW200813021A (es)
WO (1) WO2008008310A2 (es)
ZA (1) ZA200900019B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2408584C2 (ru) 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
BRPI0912826A2 (pt) * 2008-05-21 2015-07-28 Basf Se Uso de compostos, composições agroquímicas, método para combater fungos fitopatogênicos, semente, compostos, e, processo para preparar compostos
US8674105B2 (en) 2009-09-30 2014-03-18 Merck Sharp & Dohme Limited Crystalline hydrochloride salts of c-Met kinase inhibitors
US9238571B2 (en) * 2009-09-30 2016-01-19 Merck Sharp & Dohme Limited Formulations for c-Met kinase inhibitors
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
WO2015017528A1 (en) * 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
EP3628749A1 (en) * 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11369618B2 (en) * 2016-06-17 2022-06-28 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (es) 1963-04-24
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
NZ238629A (en) 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU700386B2 (en) 1995-10-16 1999-01-07 Kyowa Hakko Kogyo Co. Ltd. Triciclic compounds
CN1104428C (zh) 1996-09-13 2003-04-02 先灵公司 用作法呢基－蛋白转移酶抑制剂的取代的苯并芳庚并吡啶
CA2264569C (en) 1996-09-13 2003-11-11 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
AU2003230758A1 (en) 2002-04-02 2003-10-20 Merck And Co., Inc. 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006151809A (ja) 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
TW200738638A (en) * 2005-06-23 2007-10-16 Merck & Co Inc Tyrosine kinase inhibitors
RU2408584C2 (ru) * 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы

Also Published As

Publication number Publication date
EP2049494A2 (en) 2009-04-22
CA2656578C (en) 2012-09-04
JP4203121B1 (ja) 2008-12-24
AU2007273081A1 (en) 2008-01-17
WO2008008310A2 (en) 2008-01-17
ECSP099051A (es) 2009-02-27
US8222269B2 (en) 2012-07-17
MX2009000410A (es) 2009-01-27
ES2497493T3 (es) 2014-09-23
CN101535268B (zh) 2012-11-14
JP5245045B2 (ja) 2013-07-24
AR061804A1 (es) 2008-09-24
BRPI0713941A2 (pt) 2012-12-04
GT200900004A (es) 2010-04-13
JP2009173622A (ja) 2009-08-06
MA30631B1 (fr) 2009-08-03
KR20090026187A (ko) 2009-03-11
ZA200900019B (en) 2009-11-25
EP2049494B1 (en) 2014-06-25
PE20080275A1 (es) 2008-04-03
WO2008008310A3 (en) 2008-05-15
US20090203684A1 (en) 2009-08-13
CA2656578A1 (en) 2008-01-17
AU2007273081B2 (en) 2011-04-07
NO20090608L (no) 2009-04-14
JP2009512698A (ja) 2009-03-26
US20090012076A1 (en) 2009-01-08
TW200813021A (en) 2008-03-16
RU2009104303A (ru) 2010-08-20
HN2009000018A (es) 2011-01-24
US8101603B2 (en) 2012-01-24
CN101535268A (zh) 2009-09-16
CO6190518A2 (es) 2010-08-19
IL196337A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
ECSP099051A (es) Inhibidores de tirosina quinasa
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
NI200700318A (es) Benzocicloheptapiridinas como inhibidores de la tirosina quinasa de receptor met
WO2007149427A3 (en) Tyrosine kinase inhibitors
ECSP088540A (es) PIRROL[2,3-b]PIRIDINAS Y PIRROL[2,3-b]PIRIMIDINAS HETEROARILO SUSTITUIDAS COMO INHIBIDORES DE QUINASAS JANUS
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
SV2006002175A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina ref. pc25915a
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
BRPI0713555A2 (pt) ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
PA8624101A1 (es) Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina
NI201000143A (es) Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a] pirimidinas, procedimientos para su preparación y usos de los mismos.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
ECSP066362A (es) Inhibidores de quinesina mitótica.
WO2006124354A3 (en) Tyrosine kinase inhibitors
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
NO20070589L (no) Mitotiske kinesin-inhibitorer.
WO2006086358A3 (en) Mitotic kinesin inhibitors
WO2007050380A3 (en) Tyrosine kinase inhibitors
EP1635641A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2007050383A3 (en) Tyrosine kinase inhibitors
WO2007050401A3 (en) Tyrosine kinase inhibitors
DOP2009000004A (es) Inhibidores de tirosina quinasa
UA106222C2 (en) Poly (adp-ribose) polymerase (parp) inhibitors
TH87148B (th) สารยับยั้งไทโรซีนไคเนส

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)